
Abiomed Investor Relations Material
Latest events

Q1 2023
Abiomed
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Abiomed Inc
Access all reports
Segment Data
Access more data
Revenue by
Source
Product
Service and other
Expenses by
Financials
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It provides Impella 2.5 system, a percutaneous micro heart pump with integrated motor and sensors for use by interventional cardiologists to treat patients in cardiogenic shock; Impella CP system which enables physicians to treat patients needing circulatory support; Impella 5.0 system that provides left ventricular support; and Impella LD heart pump for use in high risk percutaneous coronary interventions.
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
ABMD
Country
🇺🇸 United States